# This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis

> **NCT07364487** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Huashan Hospital**

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** GC012F CAR-T Cell Injection

## Key facts

- **NCT ID:** NCT07364487
- **Lead sponsor:** Huashan Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-01-26
- **Primary completion:** 2026-03-25
- **Final completion:** 2026-03-25
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to the sponsor's adjustment of the research and development strategy for this clinical trial, this study was prematurely terminated, and no subjects were recruited for this study.
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07364487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07364487, "This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07364487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*